Certolizumab pegol is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:
Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
200 - 400 mg
From 200 To 400 mg once every 14 day(s)
400 mg
200 mg
The recommended starting dose of certolizumab for adult patients is 400 mg (given as 2 subcutaneous injections of 200 mg each) at weeks 0, 2 and 4.
After the starting dose, the recommended maintenance dose of certolizumab for adult patients with axial spondyloarthritis is 200 mg every 2 weeks or 400 mg every 4 weeks.
Patients who miss a dose should be advised to inject the next dose of certolizumab as soon as they remember and then continue injecting subsequent doses as instructed.
Suitable sites for injection would include the thigh or abdomen.